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Translationally controlled tumour protein TCTP (gene symbol: TPT1) is a highly-conserved, 
cyto-protective protein implicated in many physiological and disease processes, in particular 
cancer, where it is associated with poor patient outcomes. To understand the mechanisms 
underlying the accumulation of high TCTP levels in cancer cells, we studied the signalling 
pathways that control translation of TCTP mRNA, which contains a 5’-terminal oligopyrimidine 
tract (5’-TOP). In HT29 colon cancer cells and in HeLa cells, serum increases the expression of 
TCTP two- and four-fold, respectively, and this is inhibited by rapamycin or mTOR kinase 
inhibitors. Polysome profiling and mRNA quantification indicate that these effects occur at the 
level of mRNA translation. Blocking this pathway upstream of mTOR complex 1 (mTORC1) by 
inhibiting Akt also prevented increases in TCTP levels in both HeLa and HT29 colon cancer 
cells, whereas knockout of TSC2, a negative regulator of mTORC1, led to derepression of 
TCTP synthesis under serum starvation. Overexpression of eIF4E enhanced the polysomal 
association of the TCTP mRNA, although it did not protect its translation from inhibition by 
rapamycin. Conversely, expression of a constitutively-active mutant of the eIF4E inhibitor 4E-
BP1, which is normally inactivated by mTORC1, inhibited of TCTP mRNA translation in HEK293 
cells. Our results demonstrate that TCTP mRNA translation is regulated by signalling through 
the PI3-K/Akt/mTORC1 pathway. This explains why TCTP levels are frequently increased in 
cancers, since mTORC1 signalling is hyperactive in ~80% of tumours. 
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Translationally controlled tumour protein TCTP, the product of the TPT1 gene, also referred to 
as histamine-releasing factor (HRF) or fortilin, is a highly-conserved, multifunctional protein, 
which has been implicated in a range of both cell physiological and disease processes [1-4]. 
One of the best-established roles of TCTP is its anti-apoptotic, or more generally cytoprotective, 
function in cellular responses to a wide range of stresses, such as oxidative stress, heat shock, 
Ca++-stress, or stress induced by heavy metals or drug treatment [2]. This is underscored by the 
finding that gene knockout of TCTP in mice is embryonically lethal, due to excessive apoptosis 
early in embryogenesis [5-7]. TCTP has been found to bind to microtubules [8] and actin 
filaments [9], and to a range of other proteins [10]. TCTP has been implicated in the regulation 
of cell division [11], DNA damage repair [12], protein synthesis [13], and in the early 
development of both animals and plants [11, 14]. 
There is now substantial evidence demonstrating that TCTP is related to cell growth and to the 
development of cancer [1-3, 15] TCTP is overexpressed in many cancer cell lines, and its 
protein levels are positively related to properties of these cells relating to growth behaviour, 
apoptosis prevention and tumorigenicity [1, 2], and even metastatic potential [3, 15]. Increased 
TCTP levels are detected in a range of human tumours [2, 3, 15], and a high TCTP status has 
been proposed as a prognostic marker for a poor outcome in breast cancer [16], hepatocellular 
cancer [17], and in gliomas [18]. A solid understanding of how TCTP levels are regulated in 
cancer cells is therefore urgently required. Extensive work on the experimental ‘tumour 
reversion model’ has shed light on the importance of TCTP in cancer development [15, 19], and 
its anti-apoptotic activity, including the demonstrated antagonism to the tumour suppressor 
protein p53 [16, 20, 21], has been proposed as an underlying mechanism. Alternative 
mechanisms by which TCTP exerts its anti-apoptotic activity have been proposed as [2, 22]. 














example, overexpression of TCTP in HeLa cells resulted in activation of phospholipase C-, as 
well as the mitogen-activated protein (MAP)-kinase and phosphatidylinositol 3-kinase (PI3-
K)/protein kinase B (Akt) pathways [23]. Other investigations demonstrated that knock-out of 
TCTP reduces cell size and general growth in Drosophila [24]. These authors concluded that 
TCTP is an upstream regulator of mTORC1 (mammalian target of rapamycin complex 1); 
however, other studies obtained different results in mammalian cells [25, 26], so this point 
remains controversial. 
The earliest observations published on TCTP, at the time designated Q23 [27], p21 [28] or p23 
[29], described the rapid growth induction of its synthesis at the translational level as a main 
feature of the protein, supporting the notion that TCTP is important for cell growth [30]. Although 
it has meanwhile been established that TCTP levels may also be regulated by mechanisms 
other than translational control [1, 2], the cellular response to growth stimuli typically involves 
translational up-regulation of TCTP levels, at least in mammalian cells. However, the precise 
signalling pathway and mechanism involved are not yet completely characterised. We have 
previously shown that eukaryotic initiation factor 4E (eIF4E) is involved in regulating TCTP 
levels after serum stimulation of mouse fibroblasts [31]. At this time, the link between mTORC1 
and the regulation of eIF4E had not yet been established, and it is now important to examine 
whether translation of the TCTP mRNA is indeed regulated through the PI3-K/Akt/mTORC1 
signalling pathway, which is frequently hyperactive in human tumours. 
mTORC1 is the hub of a signalling network that integrates a wide range of environmental 
signals and regulates an array of important cellular processes, in particular anabolic pathways 
[32]. The best characterised role of mTORC1 is in growth signalling and the regulation of protein 
synthesis. Growth factor binding to tyrosine kinase receptors results in activation of mTORC1 
typically through the PI3-K/Akt signalling pathway [32-34], although the MAP kinase or Wnt 














GTPase Rheb (Ras homologue enhanced in brain), a direct activator of mTORC1, which is kept 
in an inactive state through the tuberous sclerosis complex TSC [37], containing the proteins 
TSC1 and 2. Growth factor signalling via PI3-K and Akt results in phosphorylation and 
inactivation of TSC2, and consequently in activation of mTORC1 [33, 36, 38]. Deregulation of 
mTORC1 is frequently observed in cancer cells reflecting the fact that many components of the 
signalling pathways upstream of mTORC1 are mutated in human cancers, as exemplified by the 
familial cell growth syndrome tuberous sclerosis [32]. 
Once activated, mTORC1 stimulates protein synthesis through at least two mechanisms, i.e. (1) 
activation of p70-S6 kinase, which phosphorylates ribosomal protein S6 (RpS6) and inhibits 
eukaryotic elongation factor 2 kinase [39], and (2) inactivation of the inhibitor of translation 
initiation factor eIF4E, eIF4E-binding protein 1 (4E-BP1). The consequences of RpS6 
phosphorylation are yet to be fully elucidated, whereas the importance of 4E-BP1 inactivation 
for the control of cap-dependent translation, cell proliferation and tumour development is well 
established [32, 40]. Activation of eIF4E through the PI3-K/Akt/mTORC1 signalling pathway is 
believed to enhance selectively the translation of mRNAs encoding proteins involved in 
important biological processes that contribute to cancer development: protein synthesis and 
ribosome biogenesis, energy metabolism, cell cycle activation, prevention of apoptosis, as well 
as promotion of angiogenesis and metastasis [32]. Translation of a particular subset of mRNAs, 
called TOP-mRNAs (based on the presence of a 5’-tract of oligopyrimidines, 5’-TOP), is 
specifically up-regulated upon mTORC1 activation, although the exact mechanism for this still 
remains to be elucidated [41, 42]. The mRNAs for ribosomal proteins and translation factors [43-
45] are the classical representatives of this group, but recently also mRNAs for other proteins 
where shown to bear this signature [45]. The mRNA coding for TCTP also contains a 5’-TOP 
[14, 30, 46]; in fact several potential TOP sequences were identified in the vicinity of its 














regulated through mTORC1, similarly to the mRNAs for other anti-apoptotic proteins, such as 
Mcl-1 [47, 48]. Here we provide the following evidence in support of this hypothesis. We show 
that the serum-stimulated induction of TCTP in HeLa cells is partially inhibited by rapamycin and 
completely blocked by mTOR kinase inhibitors, indicating that mTOR is indeed involved in 
regulating TCTP synthesis. We performed Northern blot analysis of polysome profiles to 
demonstrate that this regulation occurs at the translational level, and we provide evidence that 
Akt and TSC2 (upstream regulators of mTORC1) and eIF4E (a downstream effector) are 
involved in regulating TCTP expression. 
2. Materials and Methods 
2.1. Cell culture and treatments 
HeLa cells and HT29 colon cancer cells were grown in DMEM (Dulbecco’s Modified Eagle’s 
Medium) supplemented with 10% foetal bovine serum (FBS), glutamine and 1% 
penicillin/streptomycin. For growth-induction experiments, cells were seeded in 6-well plates 
and grown to about 70% confluence; cells were then serum-starved for a minimum of 20h. 
Growth-induction was performed by addition of 20% FBS for the indicated periods of time. 
Where indicated, the following mTOR inhibitors were added 30 min prior to serum stimulation: 
50 nM rapamycin (kindly provided by Selleck Chemicals, Houston, TX USA, to UAB), 100 nM 
AZD8055 (purchased from Selleck), 1 M PP242 (Sigma-Aldrich) or 5 M Akt inhibitor VIII 
(Calbiochem-Merck, Kilsyth, VIC Australia; the company’s datasheet states that this inhibitor 
targets all three isoforms of Akt).  
2.2. Cell lysis  
For preparation of extracts, HeLa cells were washed three times with ice-cold PBS, lysed on the 
plates by scraping in about 120 l lysis buffer (50 mM Tris/HCl, 50 mM 2-glycerophosphate, 1 














mercaptoethanol and protease inhibitor cocktail). HT-29 cells were lysed in NP40 cell lysis 
buffer (Life Technologies, Burwood, VIC Australia) with freshly added 1 mM DTT and protease 
inhibitor cocktail. Lysates were centrifuged for 10 minutes at 15 000 rpm and 4ºC. Supernatants 
were stored at –80oC and protein concentrations were determined using the Bradford assay.  
2.3. Western blotting 
Equal amounts of cell extract (typically 15 g total protein) were separated by SDS-gel 
electrophoresis on 12.5% polyacrylamide gels and electrophoretically transferred onto 
polyvinylidene difluoride (PVDF) membranes. Blots were blocked in 3% (w/v) defatted milk and 
incubated with the indicated primary antibody overnight at 4oC. For visualisation, blots were 
either incubated with fluorescently-tagged secondary antibodies and scanned using a LI-COR 
Odyssey imaging system, or alternatively, incubated with HRP-linked secondary antibodies, 
developed with Lumi-Glo (Cell Signalling Technology; Genesearch, Arundel, QLD Australia) and 
exposed to Kodak X-Omat film. After scanning (GS-800 scanner; Bio-Rad, Gladesville, NSW 
Australia), signals were quantified using the Multi-Analyst software (Bio-Rad).  
2.4. Antibodies 
The mouse monoclonal anti-TCTP antibody (AB58362) was purchased from Abcam (UK) via 
Sapphire Bioscience, Waterloo, NSW Australia. Phospho-RpS6 (Ser 240/244; #2215), phospho-
Akt (Ser 473; #9271), eIF-4E (#9742) and secondary HRP-linked antibodies were from Cell 
Signalling Technology. Anti-4EBP1 (sc6024) and anti--tubulin were obtained from Santa Cruz 
Biotechnology (Heidelberg, Germany), while anti-actin was from Sigma and anti--tubulin from 
Amersham Biosciences (UK). 
2.5. Polysome profiles and Northern blot analyses 
To generate polysome profiles, cytoplasmic cell extracts were layered onto 20–50% (w/v) 














SW41 rotor. Gradients were pumped out by upward displacement and fractionated into nine 
fractions. The absorbance at 254 nm was continuously monitored. RNA was isolated from each 
gradient fraction and processed for Northern blot analysis as previously described [49]. 
Radioactive probes were prepared by the random primer technique using DNA fragments 
isolated from plasmids containing PCR-amplified cDNA sequences. Northern blots were 
visualised and quantified using a Typhoon phosphorimager (GE Healthcare, Hatfield, Herts, UK). 
2.6. Quantification of TCTP mRNA by qPCR 
HeLa cells were grown in 12-well plates to about 70% confluence. Cells were then serum-
starved for 21 h. A subgroup of samples was re-stimulated for 6 h by addition of 20% FBS. 
Where indicated, the mTOR inhibitors rapamycin (100 nM), PP242 (1 M) or AZD8055 (100 nM) 
were present for the same time period, also in the case of serum-starved cells. All treatments 
were performed in triplicate. RNA was extracted with Tri-reagent (TR 118, Medical Research 
Centre) according to the manufacturer’s instructions. Genomic DNA was removed using the 
Ambion Turbo DNA-free kit, followed by reverse transcription using an M-MLV reverse 
transcriptase for 2 h at 37°C (M1705, Promega). Quantitative real time PCR was carried out in 
technical triplicates on a LightCycler 480 (Roche) using the SYBR select master mix (4472918, 
Life Technologies) according to manufacturer’s instructions. Reactions for each target were 
optimized for an efficiency of >1.8 and specificity was confirmed via melt curve analysis. The 
following primers (KiCqStart SYBR green, Sigma) were used: TCTP (TPT1 gene) (sense, 5’-
TACTCTTTCTGGTCTCTGTTC-3’; antisense, 5’-CAAGTTTCACAAAAGAAGCC-3’), and β2-
tubulin (B2T) (sense, 5’-AAGGACTGGTCTTTCTATCTC-3’; antisense, 5’-
GATCCCACTTAACTATCTTGG-3’) at 400 nM in 20 µl reactions with 80 ng cDNA. Treatment 
effects on mRNA expression levels were assessed using one-way ANOVA for each target. 
Statistical significance was accepted at P<0.05 and data are presented as the mean ± standard 














2.7. Overexpression studies  
To overexpress initiation factor eIF4E, HeLa cells were transiently transfected with a plasmid for 
the expression of HA-tagged human eIF4E [50] using Lipofectamine 2000 (Invitrogen) according 
to the manufacturer's protocol. The medium was changed after 5h and the cells were then 
maintained in medium containing 10% foetal calf serum for 48h.  
HEK293 cells tetracycline-inducible for the expression of eIF4E or for the expression of a non-
phosphorylatable (constitutively-active) mutant of 4E-BP1 were obtained from the lab of Dr 
Simon Cook (Babraham Institute, UK) [51].  Cells were induced for the expression of the 
respective protein by incubation with tetracycline (1 g/ml) for 48 h prior to performing the 
experiment. 
3. Results  
3.1. Growth factor-dependent induction of TCTP synthesis in cancer cells is  
sensitive to treatment with rapamycin, and particularly to mTOR kinase 
inhibitors  
TCTP is overexpressed in several human tumours, and our own preliminary data on 
immunohistostaining of human colon cancer samples indicate an overexpression of TCTP in 
adenomas and adenocarcinomas of the colon, compared to normal colon tissue (P Puri, M 
Radojkovic, P Colligan, A Lochhead & U Bommer, unpublished results). Since the PI3-K/Akt/ 
mTORC1 signalling pathway is often activated in colon cancer [52, 53], it was of interest to 
study whether this pathway is also involved in regulating TCTP levels in colon cancer cells. The 
presence of a 5’-TOP in the mRNA of TCTP does indeed suggest a possible role of the PI3-














Serum-stimulation of mouse fibroblasts was originally used to demonstrate the growth factor-
dependent regulation of TCTP synthesis [27]. We performed serum-starvation and refeeding 
experiments on HT29 colon cancer cells to study the regulation of TCTP synthesis, in presence 
or absence of rapamycin, the classical inhibitor of mTORC1 (Fig. 1A). Serum stimulation 
resulted in an about two-fold increase in TCTP levels in HT29 cells, which was completely 
inhibited by rapamycin, indicating that mTORC1 indeed regulates TCTP expression in colon 
cancer cells. As an indication for mTORC1 activity, we also analysed the phosphorylation of 
RpS6 on serine residues 240/244, specific targets for p70-S6 kinase, which is activated by 
mTORC1. The observation that RpS6 phosphorylation is fully inhibited by rapamycin indicates 
that mTORC1 is indeed inactivated by this treatment in HT29 colon cancer cells. 
Next, we chose HeLa cells to see whether the rapamycin-sensitive induction of TCTP synthesis 
is also observed in other cancer cell types. We found that the response to serum stimulation in 
terms of relative increase of cellular TCTP levels is about four-fold in these cells (Fig. 1B), which  
resembles the level of induction previously observed in murine cell lines [29, 54]. We also 
observed that in HeLa cells, rapamycin only partially blocked the serum-induced increase of 
TCTP levels. Rapamycin inhibits mTORC1 by binding together with the FKBP12 protein to a site 
adjacent to the kinase domain of mTOR [55], but does not inhibit all functions of mTORC1 [56, 
57]. Therefore, we made use of two of the more recently-developed mTOR kinase inhibitors 
(mTOR-KIs), which directly block the kinase activity of mTOR, i.e. PP242 [57] and AZD8055 
[58]. In contrast to rapamycin, these mTOR kinase inhibitors do completely block serum-induced 
TCTP accumulation in HeLa cells (Fig. 1B), which further confirms that mTOR is likely to be 
involved in the regulation of TCTP synthesis under these conditions. On the other hand, the 
incomplete effect of rapamycin in blocking the increase in TCTP levels does not reflect a partial 














not shown). Rather, additional, rapamycin-insensitive but mTOR-dependent signalling events 
appear to be involved. 
The accumulation of the TCTP protein after serum stimulation of cells could principally be due to 
protein stabilisation and/or an increased rate of synthesis. In a recent study, we applied the 
method of pulsed stable isotope labelling with amino acids in cell culture (pSILAC) to assess the 
relative rate of synthesis of individual proteins in HeLa cells over a period of 6 h, in the presence 
or absence of rapamycin or the mTOR-KIs PP242 or AZD8055 [59]. This method measures the 
de novo rate of accumulation of specific proteins, which are identified and quantitated by mass 
spectrometry. In this way, we generated a large dataset that allowed us to distinguish which 
proteins are specifically regulated through mTORC1, i.e., whose rates of synthesis are sensitive 
to inhibition by rapamycin or mTOR-KIs, from those ones that are not. Inspection of this dataset 
revealed that TCTP mRNA behaves like known TOP mRNAs, in that the rate of synthesis of 
TCTP is inhibited by rapamycin (about 50%) and more strongly (about 80%) by the mTOR-KIs 
PP242 or AZD8055 (Fig. 1C). In contrast, the degree of inhibition by mTOR-KIs for proteins 
encoded by non-TOP mRNAs, such as hnRNP-A3 (right panel), is typically much weaker (in the 
range of 40%), and the inhibition by rapamycin of the synthesis of this and other proteins  
encoded by non-TOP mRNAs is on average only about 14% [59]. 
3.2. Serum induction of TCTP synthesis occurs at the level of translation and is 
completely inhibited by mTOR kinase inhibitors 
The pSILAC data demonstrate that the serum-induced increase in TCTP levels is likely due to 
an increase in its rate of synthesis and the results with the mTOR kinase inhibitors indicate that 
this is driven by mTORC1 signalling. To assess whether the observed regulation of TCTP 
synthesis is associated with alterations in TCTP mRNA levels, we subjected HeLa cells to the 














refeeding with 20% FBS, both in the presence or absence of mTOR kinase inhibitors, and 
performed TCTP mRNA quantification by Real-Time-qPCR (Fig. 2A). The results clearly show 
that TCTP mRNA levels are not affected by serum starvation/refeeding or by mTOR kinase 
inhibitors. 
To demonstrate that the increase in TCTP synthesis is actually regulated at the level of 
translation of its mRNA, we monitored the polysomal distribution of TCTP mRNA in the 
presence and absence of mTOR inhibitors. In such experiments, translationally active 
polysome-associated mRNAs are resolved from non-polysomal mRNAs. This is detected by 
Northern blotting of the corresponding fractions from the sucrose density gradient (Fig. 2B). The 
top panels show the absorbance profiles of the gradients, i.e. the ribosome (rRNA) distribution, 
of the HeLa cell extracts after the indicated treatments. The Northern blots were probed for 
TCTP mRNA, the mRNA for RpS7, a known TOP mRNA [43], and also for the mRNA of the 
RNA binding protein hnRNP-A3, the translation of which is not regulated by mTORC1 (see Fig. 
1C). Blots were quantified and the percent mRNA per fraction was plotted in the graphs in the 
bottom panel. The total percentage of mRNA present in the polysomal fractions (fractions 5-8), 
i.e. in the translationally active state, were calculated and plotted in the graph shown in Fig. 2C. 
The Northern blot data for the reference mRNAs, RpS7, a classical TOP mRNA, and hnRNPA3, 
a non-TOP mRNA, are shown only from one experiment here, since we have published similar 
data before [59, 60]. Our results demonstrate that, under serum-starved conditions, only a small 
proportion (25-30%) of TCTP mRNA is in the polysomal fraction, whereas after serum 
stimulation for 6h  about 50% of TCTP mRNA had shifted into the polysome region of the 
gradient, clearly indicating that serum stimulation results in activation of the translation of a 
substantial proportion of this mRNA (Fig. 2C). This shift of the TCTP mRNA into polysomes is 
strongly inhibited by rapamycin and is completely prevented by the mTOR-KIs AZD8055 or 














although the shifts into and out of polysomes are more pronounced in the case of the ribosomal 
protein mRNA (from 30 to 70%; Fig. 2C). In contrast, the mRNA for hnRNP-A3 displayed a 
completely different behaviour; at least 60% of this mRNA remained in polysomes under all 
conditions tested; and none of the mTOR inhibitors substantially affected its polysomal 
association. These results clearly demonstrate that the TCTP mRNA behaves as a typical TOP 
mRNA, in that it is regulated at the level of recruitment into polysomes, i.e. at translation 
initiation, by mTORC1 signalling (Fig. 2B,C). Thus, mTOR signalling positively regulates the 
translation of the TCTP mRNA, but not its level of expression (Fig. 2A). 
3.3. TCTP synthesis is regulated by the Akt pathway upstream of mTORC1 
We then asked whether elements of the signalling pathway upstream of mTORC1 participate in 
the growth-dependent regulation of TCTP synthesis. First, we used Akt inhibitor VIII 
(Calbiochem), which inhibits all three Akt isoforms, to see whether it prevents serum-induced 
increase of TCTP levels in HeLa cells. Probing immunoblots with antibodies specific for 
phospho-Akt (Ser473) showed that Akt phosphorylation is indeed blocked under these 
conditions (Fig. 3A, right graph), in some blots even completely. This compound blocked the 
serum-induced accumulation of TCTP in HeLa cells, similarly to mTOR kinase inhibitors (Fig. 3A, 
left graph). Since we were particularly interested to probe whether the PI3-K/Akt pathway is 
involved in regulating TCTP levels in colon cancer cells, we also tested the effect of the Akt 
inhibitor on TCTP levels in HT29 cells. As shown in Fig. 3B, it fully blocked the ability of serum 
to increase TCTP protein levels. 
Active Akt phosphorylates and inactivates the TSC complex, an important inhibitor of mTORC1, 
it therefore promotes mTORC1 signalling.To study the influence of the TSC complex on TCTP 
protein expression, we made use of mouse embryonic fibroblasts (MEFs) from TSC2-knockout 














expression levels of TCTP are generally two-fold higher in the TSC2-KO cells compared to wild-
type cells. We also observed that TCTP levels are down-regulated during serum-starvation (the 
0 h time-point) in wildtype cells, whereas this effect is not seen TSC2-KO cells (Fig. 4, left graph 
and top western blot). Monitoring the levels of RpS6 phosphorylation (Fig. 4, right graph and 
bottom western blot) confirmed that, as expected, mTORC1 signalling is constitutively activated 
in TSC2-KO cells, including in serum-starved cells (0 h), whereas it is very low in serum-starved 
wildtype cells. Taken together, the data in Figs. 3 and 4 imply that both the tuberous sclerosis 
complex and Akt participate in the serum-dependent regulation of TCTP levels.  
 
3.4. The downstream targets of mTORC1, 4E-BP1, and its binding partner, 
initiation factor eIF4E, are involved in regulating TCTP mRNA translation.   
The best-characterised output of mTORC1 activity that impinges on mRNA translation initiation 
is the phosphorylation and concomitant inactivation of 4E-BP1, resulting in the increased 
availability of eIF4E to engage in translation initiation [42, 61]. To initially assess whether eIF4E 
plays a role in regulating TCTP mRNA translation, we transiently transfected HeLa cells with a 
vector encoding HA-tagged human eIF4E and analysed the polysomal distribution of TCTP 
mRNA in cells with and without overexpressed eIF4E. In this system, eIF4E overexpression 
caused a substantial increase in the polysomal association of TCTP mRNA (Fig. 5; left panels). 
This effect was reversed by treatment with rapamycin, indicating that eIF4E is unable to 
override the inhibitory effect of this mTORC1 inhibitor. We also probed the blots for the mRNA 
for RpS7, another TOP-mRNA, and found that it behaved very similarly to the TCTP mRNA (Fig. 
5; right panels). Similar results were also obtained for the mRNA for another ribosomal protein 
(TOP) mRNA, RpL11 [59]. 
To assess the importance of eIF4E and 4E-BP1 for the control of TCTP mRNA translation, we 














of eIF4E or a constitutively active mutant of 4E-BP1, respectively [51]. Fig. 6A demonstrates 
that overexpression of eIF4E in HEK293 cells resulted in an about 1.3-fold increase in the 
polysomal association of TCTP mRNA, which is prevented in the presence of rapamycin.  
Compared to the situation observed in HeLa cells (Fig. 5), the relative shift of the TCTP mRNA 
into polysomes and its inhibition by rapamycin was less pronounced in these cells. The mRNA 
for RpS6, another TOP message, displayed a similar behaviour, although the polysomal shift 
caused by eIF4E overexpression and the effect of rapamycin was more pronounced for this 
mRNA, compared to TCTP mRNA. In contrast, the (non-TOP) actin mRNA was already heavily 
associated with polysomes and its polysomal association was only affected to a small extent by 
overexpressing eIF4E or by rapamycin (Fig. 6A). Expression of a constitutively active 
(phosphorylation-defective) mutant of 4E-BP1 in HEK293 cells resulted in a similar (20-30%) 
inhibition of polysomal association of all three mRNAs (Fig.6A). This indicates that 4E-BP1 does 
play a role in regulating the translation of the TCTP mRNA, but that this reflects a rather general 
effect, not one specific for TOP mRNAs. Further data for Rp and actin mRNAs obtained with this 
tet-inducible HEK293 cell system have been submitted elsewhere for publication. 
We also tested whether the activation of translation of the TCTP mRNA by increased eIF4E 
levels is reflected in TCTP protein levels. Expression of eIF4E was induced in HEK293 cells by 
treatment with tetracycline for 48 h. Cells were then subjected to serum-starvation and 
subsequent re-feeding. Under both conditions, TCTP protein levels were higher in eIF4E-
overexpressing cells than in control cells (Fig. 6B), confirming that eIF4E does promote TCTP 
expression, relative to that of actin, even under serum-starved conditions. We also tested the 
effect of the interfering mutant of 4E-BP1 on TCTP expression levels by Western blotting and 
found that it substantially reduced TCTP levels in HEK293 cells (Fig. 6C). Taken together, these 
studies demonstrate that 4E-BP1 levels and eIF4E availability can both contribute markedly to 















Initial evidence for the translational regulation of TCTP synthesis came from the observation 
that the TCTP (P21) mRNA is stored in cytoplasmic untranslated mRNP particles [28], and from 
the rapid induction by serum in the rate of TCTP (‘Q23’ or ‘P23’) synthesis, which is not 
impaired by inhibitors of transcription, such as actinomycin D [29]. However the mechanism(s) 
regulating the translation of its mRNA had not previously been fully characterised. 
Demonstration of the importance of initiation factor eIF4E for the translational regulation of 
growth-regulatory mRNAs [62] prompted us to study the involvement of this factor in the control 
of TCTP (P23) synthesis, which provided evidence in support of this [31]. At that time, the 
prevailing view was that eIF4E activity is particularly required for highly structured mRNAs that 
are otherwise poorly translated [63], and the link between the mTORC1 pathway and control of 
eIF4E availability was only established later.  
A characteristic feature of the TCTP mRNA is the presence of a 5’-TOP [14, 30, 45, 46], which 
is found in many mRNAs whose translation is controlled through mTORC1 signalling. This 
prompted us to undertake the present study, which was aimed at exploring the involvement of 
the Akt/mTORC1 signalling pathway in the translational regulation of TCTP synthesis in cancer 
cells. In both HT29 colon cancer cells (Fig.1A) and HeLa cells (Fig. 1B), the allosteric mTORC1 
inhibitor rapamycin substantially inhibited serum-dependent TCTP accumulation, but in HeLa 
cells it did not do so completely. In contrast, two recently-developed mTOR kinase inhibitors, 
PP242 and AZD8055, each completely inhibited the induction of TCTP in HeLa cells (Fig. 1B). 
These results provide clear evidence for the involvement of mTOR signalling in the serum-
dependent induction of TCTP synthesis. Partial inhibition of synthesis by rapamycin and strong 
inhibition by mTOR-KIs is observed for many proteins, including proteins encoded by TOP 
mRNAs [59, 64, 65]. Our own study employing the pSILAC method, which measures de novo 














The data obtained for TCTP by this method support the conclusion that de novo synthesis of 
TCTP is positively regulated by mTORC1 activity (Fig. 1C). Two other studies used ribosome 
profiling in combination with deep-sequencing to generate transcriptome-wide datasets of 
mTORC1-regulated mRNAs [64, 65]. Compilation of the results for the TCTP mRNA/protein 
from all three papers (Table 1) shows that for TCTP, both methods yield very similar results, 
indicating that all mTOR kinase inhibitors tested (Torin 1, PP242 and AZD8055) inhibit TCTP 
mRNA translation by at least 80% (more strongly than many other TOP mRNAs), whereas 
rapamycin resulted in only slightly more than 50% inhibition (similar to many other TOP mRNAs). 
Similar results were obtained in all three mammalian cell types investigated (Table 1). These 
data also correspond well with our findings for HeLa cells, demonstrating (1) that the serum-
induced increase in TCTP levels is inhibited by around 50% by rapamycin and completely 
prevented by mTOR-KIs (Fig.1B) and (2) that  this effect involves translational up-regulation 
(recruitment of the mRNA into polysomes) which is prevented by mTOR-KIs (Fig. 2B).   
We also asked whether components upstream of mTORC1 are involved in growth-dependent 
up-regulation of TCTP synthesis. An inhibitor of Akt, a kinase which indirectly activates 
mTORC1 by phosphorylating TSC2, completely prevented induction of TCTP in both HeLa (Fig. 
3A) and HT29 colon cancer cells (Fig. 3B). The latter finding also supports our hypothesis that 
the increased expression levels of TCTP observed in adenocarcinomas of the colon (our 
unpublished immunohistochemistry results) are likely to be caused by increased signalling 
through the PI3-K/Akt pathway, an effect which is frequently observed in colon cancer [52, 53]. 
Similar to the observations of [66], we find that MEFs from TSC2-knockout mice have lost their 
ability to repress both mTORC1 activity (assessed by monitoring RpS6 phosphorylation) and 
TCTP synthesis in response to serum starvation (Fig. 4). Overall, the results obtained with the 
Akt inhibitor and with the MEFs from TSC2-KO mice clearly support the view that TCTP 














We also studied the effect of downstream effectors of mTORC1 on TCTP mRNA translation. 
Since activation of mTORC1 increases the availability of eIF4E through inactivation of 4E-BP1 
[42, 61], we asked whether increased levels of eIF4E contribute to activation of TCTP mRNA 
translation and whether it is impaired by increased activity of 4E-BP1. Our results demonstrate 
that increased eIF4E levels are able to drive the TCTP mRNA into heavy polysomes in both 
HeLa cells (Fig. 5) and HEK293 cells (Fig.6A), although the extent to which this occurs differs 
between different the two cell lines. Generally, we observe in our polysome profiling 
experiments (Figs. 2, 5 and 6) that the responses of the TCTP mRNA to alterations of cellular 
conditions (in terms of polysome shift) are less than that of the ribosomal protein mRNAs, the 
classical TOP mRNAs. However, the general pattern of behaviour (response to serum 
stimulation or sensitivity to mTOR inhibition) is very similar between TCTP mRNA and Rp 
mRNAs, which underscores the classification of TCTP mRNA as a TOP-mRNA. 
The polysome profiling results obtained from HeLa cells (Fig. 5) show that, in this cell line, 
eIF4E overexpression cannot overcome the inhibitory effects of rapamycin, indicating that 
additional mechanisms are involved in the mTORC1-dependent regulation of TCTP mRNA 
translation. Our results obtained by Western blotting (Fig. 6B) confirm that eIF4E levels do 
indeed have a considerable effect on TCTP protein accumulation in HEK293 cells. They also 
show that eIF4E can partially overcome the inhibitory effect of serum starvation on TCTP 
protein levels, complementing our earlier findings obtained in murine fibroblasts overexpressing 
eIF4E [31].  
Since 4E-BP1, rather than eIF4E itself, is the direct target of mTORC1, we also asked whether 
4E-BP1 affects TCTP mRNA translation. Our results show that expression of a constitutively-
active mutant of 4E-BP1 in HEK293 cells resulted in the partial release of the TCTP mRNA from 
heavy polysomes (Fig. 6A), and also in a significant reduction of cellular TCTP levels (Fig. 6C). 
These findings clearly establish the involvement of 4E-BP1 in the control of TCTP mRNA 














similar to that of TCTP mRNA. We also observed that the polysomal association of the (non-
TOP) actin mRNA, was significantly decreased by mutant 4E-BP1 (Fig. 6A). This indicates that 
the effect of 4E-BP1 is a rather general one and is not restricted to TOP-mRNAs. This point 
requires future investigation, particularly in the light of recent data indicating that the eIF4E/4E-
BP system is unlikely to be involved in the oxygen-dependent regulation of TOP mRNA 
translation via mTORC1 [67].  
Taken together, the present data strongly support the conclusion that the TCTP mRNA belongs 
to the set of 5’-TOP mRNAs, the translation of which is specifically regulated through the 
mTORC1 pathway. This group of translationally controlled proteins includes Rps and other 
components of the translational apparatus of the cell [43-45]. More recently, many additional 
mRNAs containing a 5’-TOP, have been found to be regulated by mTORC1 [45, 59, 64, 65].  
TCTP has been characterised as an anti-apoptotic protein [1, 2, 68] and this fits with its 
identification as a member of the set of mTORC1-regulated proteins. Other established 
examples of such translationally-regulated anti-apoptotic proteins include Bcl-2 and Bcl-XL [69], 
Mcl-1 [47, 48, 69] and survivin [32]. Interestingly, Bcl-XL and Mcl-1 have also been shown to be 
interaction partners for TCTP [68]. These proteins can be considered as survival factors that 
may be required by the cell in rapid responses to environmental stimuli, which is why fast-acting 
translational regulation of their synthesis is advantageous. We also found previously that down-
regulation of TCTP may occur at the translational level, through activation of protein kinase PKR 
[54, 70], a mechanism similarly reported for Mcl-1 [71]. 
There is overwhelming evidence that the PI3-kinase/Akt/mTORC1 pathway is closely linked to 
tumorigenesis [32, 36, 48, 52, 53]. In particular, the 4E-BP1/eIF4E axis downstream of 
mTORC1 has been implicated in promoting cancer, through the translational activation of 
mRNAs encoding proteins involved in cell proliferation [40] and in tumour initiation and 














translational activation of the anti-apoptotic protein Mcl-1 for cell survival [47] and for cancer 
initiation and progression [48]. As a further anti-apoptotic protein involved in cancer progression 
[1-3, 68, 72], TCTP is thus clearly part of the protein network involved in mTOR-dependent 
cancer promotion, as was recently demonstrated for neurofibromatosis type 1-associated 
tumours [73]. Antagonism to the tumour suppressor p53 has been proposed as an important 
mechanism of TCTP’s cancer promoting activity [16, 20, 21]. Since p53 interferes with the PI3-
K/Akt/mTORC1 pathway by inducing its negative regulators PTEN and TSC2 [74], our present 
findings imply that p53 also antagonises TCTP expression at the translational level, hence 
adding another layer of regulation to the complex interplay between p53 and TCTP. 
 
5. Conclusion 
Serum stimulation of HeLa and HT29 colon cancer cells results in an up to five-fold increase in 
cellular TCTP levels. This effect is partially inhibited by rapamycin and completely blocked by 
mTOR kinase inhibitors. Northern blot analyses of polysome profiles show that serum 
stimulation results in mTORC1-dependent activation of TCTP mRNA translation. Upstream 
effectors of mTORC1, Akt and TSC-2, are also involved in the regulation of TCTP synthesis, as 
are its downstream effectors eIF4E and 4EBP1. These results demonstrate that TCTP levels 
are regulated through the PI3-kinase/Akt/mTORC1 signalling pathway, which is frequently 
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Figure legends  
Fig. 1  The serum-induced increase in TCTP levels in cancer cells is inhibited by rapamycin and 
mTOR kinase inhibitors. (A) HT29 colon cancer cells were starved of serum overnight and re-
stimulated with 20% FBS for the indicated periods of time. Where indicated, 50 nM rapamycin 
was added 30 min before serum. Relative levels of TCTP (and -tubulin as a loading control) 
were assessed in cell extracts by Western blotting. As an indicator of mTORC1 activity, levels of 
phosphorylated RpS6 (Ser240/244) were assessed. (Open bars: without rapamycin, filled bars: 
with rapamycin). (B) HeLa cells were starved of serum overnight and re-stimulated with 20% 
FBS for the indicated periods of time. Where indicated, rapamycin or the mTOR kinase 
inhibitors PP242 (1 M) or AZD8055 (100 nM) were added 30 min before stimulation with serum. 
Relative levels of TCTP and of -tubulin, as a loading control, were assessed by Western 
blotting. Average values from three independent experiments were plotted (± SD), compared to 
the serum-starved control.  (C) De novo synthesis of TCTP is blocked by mTOR kinase 
inhibitors. Levels of newly-synthesised proteins, over a period of 6h, were assessed in HeLa 
cells incubated in the absence or presence of the mTORC1 inhibitors rapamycin, PP242 or 
AZD8055, using the pSILAC (pulsed stable isotope labelling with amino acids in cell culture) 
method. The data are taken from the recently published dataset [59] and plotted relative to the 
untreated control. For comparison, the results for hnRNPA3, a protein whose synthesis is not 
regulated through mTORC1, are shown.  
Fig. 2  The serum-stimulated activation of TCTP mRNA translation is blocked by mTOR kinase 
inhibitors. A) Cellular TCTP mRNA levels are not affected by serum starvation and by refeeding, 
or by mTOR inhibitors. Levels of the TCTP mRNA were assessed by qPCR in HeLa cells either 
serum-starved for 21 h, or subsequently re-stimulated with serum for 6h with 20% FBS, as 
indicated below the graph. Where indicated, rapamycin (100 nM) or the mTOR kinase inhibitors 














or throughout the period of serum stimulation. Ct-values for TCTP mRNA were normalised 
against 2-tubulin mRNA and plotted as percentage relative to the serum-starved control. The 
bars represent the average from three independent experiments (± SEM). 
B) HeLa cells were serum-starved overnight (all parts) and then re-stimulated for 6 h with 20% 
FBS (except for the left-most panel). Where indicated, rapamycin or the mTOR KIs PP242 (1 
M) or AZD8055 (100 nM), were added 30 min before stimulation with serum. Cell lysates were 
fractionated on sucrose gradients and absorbance was monitored at 254 nm. The traces are 
shown at the same scale for each panel; the positions of 40S, 60S and 80S ribosomal particles 
are indicated in the left panel. Bars at the bottom of each panel/graph indicate the position of 
polysomes. Northern blots were prepared from all fractions and probed for mRNAs of TCTP, 
RpS7 and hnRNP-A3. Blots were quantified and the percent mRNA in each fraction is plotted in 
the graphs displayed below the Northerns. C) The percent of mRNA present in the polysome 
fractions was calculated for each blot and plotted in the graph. The data for TCTP mRNA 
represent the average from two independent experiments. 
Fig. 3  Serum induction of TCTP levels is blocked by an inhibitor of Akt. (A) HeLa cells were 
starved of serum for 24 h and then re-stimulated with 20% FBS for the indicated periods of time. 
Where indicated, the Akt inhibitor VIII was added at 5 M 30 min before stimulation. Relative 
levels of TCTP and of -tubulin as a loading control were assessed by Western blotting. 
Phosphorylation of Akt (at Ser473) was also monitored. (B) HT29 colon cancer cells were 
treated in the same way as HeLa-cells. Relative levels for TCTP, and for -tubulin, were 
assessed by Western blotting (open bars: no inhibitor; filled bars: Akt inhibitor). Graphs 
represent averages of three independent experiments (± SD). 
Fig. 4  Knockout of tuberous sclerosis complex 2 (TSC2) results in constitutive expression of 
TCTP, even during serum starvation. Mouse embryonic fibroblasts (MEFs) from TSC2-KO mice 














FBS for the indicated periods of time. Relative levels of TCTP and -tubulin were assessed by 
Western blotting. To monitor mTORC1 activity, levels of RpS6 phosphorylation (Ser240/244) 
were also determined. Graphs showing relative TCTP levels (left) and RpS6 phosphorylation 
(right) represent the average of two independent experiments, normalised to the tubulin loading 
control (open bars: wild-type MEFs; filled bars: TSC2-KO MEFs). 
Fig. 5  Overexpression of eIF4E enhances TCTP mRNA translation in HeLa cells, but does not 
overcome the inhibitory effect of rapamycin. HeLa cells were transfected with an expression 
vector for HA-tagged eIF4E or left un-transfected, as indicated. Cells were either kept at normal 
growth conditions (top two panels) or treated for 6 h with rapamycin. Polysome profiles were 
generated from cytoplasmic cell extracts, and probed by Northern blotting for the distribution of 
the mRNAs of TCTP and of RpS7, as another TOP mRNA (blots at the top). Graphs show the 
quantified distribution of these mRNAs under all three conditions; the bottom graphs display the 
percentage of the given mRNA in polysomes. For the TCTP mRNA, the average of two 
independent experiments is shown.  
Fig. 6  eIF4E and 4E-BP1 levels affect TCTP mRNA translation and protein levels in HEK293 
cells. (A) HEK293 cells were either not induced, where indicated, or treated for 48h with 
tetracycline to induce overexpression of eIF4E or a non-phosphorylatable (constitutively-active) 
mutant of 4E-BP1. Where indicated, cells were subjected to an additional 6 h treatment with 
rapamycin. Polysome profiles were generated from cytoplasmic cell extracts, fractions collected, 
and probed by Northern blotting for the distribution of the following mRNAs: TCTP, RpS6 and 
actin (left and centre sections). Graphs on the right show the percentage of each mRNA in 
polysomes for all conditions and mRNAs. For TCTP mRNA the average of two independent 
experiments is shown. (B) Western blot showing the effect of eIF4E overexpression on TCTP 
protein levels in HEK293 cells. Cells were either left uninduced (control) or induced for 48 h with 














or serum-starved overnight and restimulated with 20% foetal bovine serum for 6h (+ FBS). 
Immunoblots were probed for TCTP, eIF4E and actin as loading control. The graph shows the 
relative TCTP levels normalised for actin, the ratio for control cells being set as 1.  (C) 
Expression of a constitutively-active mutant of 4E-BP1 reduces TCTP protein levels in HEK293 
cells. Cells were either not induced (-) or induced by tetracycline for 48 h (+) to induce the 
expression of the constitutively-active mutant of 4E-BP1 as indicated. Western blots were 
probed for TCTP, 4E-BP1 or actin as loading control. The graph shows relative TCTP levels 










































































































































































































(Summary of data from three independent 
datasets) 
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1
Relative TCTP expression refers to translational efficiency (ribosome 
profiling) or rate of de-novo TCTP protein 
synthesis (pSILAC), relative to untreated control. Data for the TCTP protein 
(Tpt1 gene) were taken from the   datasets published in the supplementary 



















Bommer et al, Growth-factor dependent expression of the translationally controlled 
tumour protein TCTP is regulated through the PI3K/Akt/mTORC1 signalling pathway. 
 
Highlights 
 TCTP is often overexpressed in cancers, where it is associated with a poor outcome.  
 We studied the signalling pathway involved in serum-induction of TCTP synthesis. 
 mTOR kinase inhibitors prevent growth-associated increase in TCTP mRNA translation. 
 The upstream effectors of mTORC1, Akt and TSC-2, also regulate TCTP expression. 
 Activation of eIF4E/inhibition of 4E-BP1 is important for efficient TCTP mRNA translation. 
